Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Int Braz J Urol ; 36(1): 75-85, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20202239

RESUMO

PURPOSE: To compare the efficacy and costs of circumcision versus topical treatment using a prospective pharmacoeconomic protocol. MATERIALS AND METHODS: We treated 59 patients (3-10 years of age) randomized into two groups: 29 underwent an 8-week course of topical treatment with 0.2% betamethasone-hyaluronidase cream twice a day; and 30 underwent circumcision. Topical treatment success was defined as complete exposure of the glans. In cases of treatment failure, circumcision was performed and its cost imputed to that of the initial treatment. The pharmacoeconomic aspects were defined according to the Brazilian National Public Health System database and the Brazilian Community Pharmacies Index. RESULTS: The two groups were statistically similar for all clinical parameters evaluated. Topical treatment resulted in complete exposure of the glans in 52% of the patients. Topical treatment was associated with preputial pain and hyperemia. However, treatment suspension was unnecessary. Minor complications were observed in 16.6% of the surgical group patients. The mean cost per patient was US$ 53.70 and US$ 125.20, respectively, for topical steroid treatment (including the costs related to treatment failure) and circumcision. The total costs were US$ 2,825.32 and US$ 3,885.73 for topical treatment and circumcision, respectively. CONCLUSIONS: Topical treatment of phimosis can reduce costs by 27.3% in comparison with circumcision. Therefore, topical treatment of phimosis should be considered prior to the decision to perform surgery.


Assuntos
Betametasona/uso terapêutico , Circuncisão Masculina/métodos , Hialuronoglucosaminidase/uso terapêutico , Fimose/tratamento farmacológico , Fimose/cirurgia , Administração Tópica , Betametasona/administração & dosagem , Criança , Pré-Escolar , Circuncisão Masculina/economia , Análise Custo-Benefício , Humanos , Hialuronoglucosaminidase/administração & dosagem , Masculino , Fimose/economia , Estudos Prospectivos , Resultado do Tratamento
2.
Int. braz. j. urol ; 36(1): 75-85, Jan.-Feb. 2010. ilus, graf, tab
Artigo em Inglês | LILACS | ID: lil-544078

RESUMO

Purpose: To compare the efficacy and costs of circumcision versus topical treatment using a prospective pharmacoeconomic protocol. Materials and methods: We treated 59 patients (3-10 years of age) randomized into two groups: 29 underwent an 8-week course of topical treatment with 0.2 percent betamethasone-hyaluronidase cream twice a day; and 30 underwent circumcision. Topical treatment success was defined as complete exposure of the glans. In cases of treatment failure, circumcision was performed and its cost imputed to that of the initial treatment. The pharmacoeconomic aspects were defined according to the Brazilian National Public Health System database and the Brazilian Community Pharmacies Index. Results: The two groups were statistically similar for all clinical parameters evaluated. Topical treatment resulted in complete exposure of the glans in 52 percent of the patients. Topical treatment was associated with preputial pain and hyperemia. However, treatment suspension was unnecessary. Minor complications were observed in 16.6 percent of the surgical group patients. The mean cost per patient was US$ 53.70 and US$ 125.20, respectively, for topical steroid treatment (including the costs related to treatment failure) and circumcision. The total costs were US$ 2,825.32 and US$ 3,885.73 for topical treatment and circumcision, respectively. Conclusions: Topical treatment of phimosis can reduce costs by 27.3 percent in comparison with circumcision. Therefore, topical treatment of phimosis should be considered prior to the decision to perform surgery.


Assuntos
Criança , Pré-Escolar , Humanos , Masculino , Betametasona/uso terapêutico , Circuncisão Masculina/métodos , Hialuronoglucosaminidase/uso terapêutico , Fimose/tratamento farmacológico , Fimose/cirurgia , Administração Tópica , Betametasona/administração & dosagem , Análise Custo-Benefício , Circuncisão Masculina/economia , Hialuronoglucosaminidase/administração & dosagem , Estudos Prospectivos , Fimose/economia , Resultado do Tratamento
3.
J Pediatr Surg ; 39(9): 1333-7, 2004 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-15359386

RESUMO

PURPOSE: The authors present here 5 cases of continent urinary diversion in rhabdomyosarcoma applying a recently described technique for the Mitrofanoff Principle devised by the authors. METHODS: Two previously irradiated rhabdomyosarcoma patients presenting with residual bladder disease and massive sensitive urinary urgency underwent a transverse colonic reservoir with catheterizable stoma. Two other patients presenting with a Bricker conduit underwent conversion into an ileal reservoir. One patient underwent reconstruction after a cystectomy. RESULTS: All patients were continent and able to perform continent intermittent catheterization. CONCLUSIONS: The technique proved to be feasible for this group of patients. The authors believe that because of its simplicity, it should be an option of continent urinary diversion when the Mitrofanoff Principle is considered.


Assuntos
Rabdomiossarcoma/cirurgia , Derivação Urinária/métodos , Neoplasias Urogenitais/cirurgia , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Quimioterapia Adjuvante/efeitos adversos , Criança , Pré-Escolar , Colo Transverso/cirurgia , Bolsas Cólicas , Terapia Combinada , Ciclofosfamida/administração & dosagem , Cistectomia , Dactinomicina/administração & dosagem , Evolução Fatal , Feminino , Seguimentos , Humanos , Lactente , Masculino , Neoplasias da Próstata/tratamento farmacológico , Neoplasias da Próstata/radioterapia , Neoplasias da Próstata/cirurgia , Radioterapia Adjuvante , Rabdomiossarcoma/tratamento farmacológico , Rabdomiossarcoma/radioterapia , Rabdomiossarcoma Alveolar/tratamento farmacológico , Rabdomiossarcoma Alveolar/radioterapia , Rabdomiossarcoma Alveolar/cirurgia , Sepse/etiologia , Neoplasias Uretrais/tratamento farmacológico , Neoplasias Uretrais/radioterapia , Neoplasias Uretrais/cirurgia , Neoplasias da Bexiga Urinária/tratamento farmacológico , Neoplasias da Bexiga Urinária/radioterapia , Neoplasias da Bexiga Urinária/cirurgia , Cateterismo Urinário , Infecções Urinárias/etiologia , Neoplasias Urogenitais/tratamento farmacológico , Neoplasias Urogenitais/radioterapia , Neoplasias Vaginais/tratamento farmacológico , Neoplasias Vaginais/radioterapia , Neoplasias Vaginais/cirurgia , Vincristina/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA